Experimental Research Article

Effects of postconditioning with N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine in isolated rat hearts

Joon Hong Kim², Joon Kim², Yong-Hyeon Park², Kook Jin Cheun², and Young-Ho Jang¹,²

¹Department of Anesthesiology and Pain Medicine, Pureun Burn Hospital, Daegu, ²Institute of Cardiovascular Research, Pusan National University Yangsan Hospital, Yangsan, Korea

Background: It was reported that N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine (TPEN), a transition metal chelator, confers cardioprotection against myocardial ischemic injury. In this study, we investigated the effect of TPEN targeting reperfusion period in isolated rat hearts.

Methods: Langendorff perfused rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. Hearts were randomly assigned to either control (n = 9) or 10 μM of TPEN (n = 8) groups. TPEN was perfused for a period of 5 min before and 30 min after reperfusion.

Results: The ratio of infarct area/ischemic area (AN/AR) was significantly reduced in TPEN treated hearts (6.9 ± 1.7%, P < 0.001) compared to control hearts (29.5 ± 3.2%). Recovery of left ventricular developed pressure (LVDP), rate-pressure product (RPP), +dP/dt_{max}, and −dP/dt_{min} in the control group after reperfusion were 53.8 ± 6.2%, 51.0 ± 6.3%, 51.9 ± 5.7%, and 51.4 ± 5.7%, respectively, of the baseline levels. In the TPEN group, LVDP, RPP, +dP/dt_{max}, and −dP/dt_{min} returned to 58.5 ± 4.6%, 54.8 ± 6.4%, 61.7 ± 4.9%, and 53.4 ± 3.9%, respectively, of the baseline levels. There were no significant differences in the cardiodynamic variables between the two groups (P > 0.05).

Conclusions: Pharmacological postconditioning with TPEN reduces myocardial infarction however, TPEN does not modify post-ischemic systolic dysfunction in isolated rat hearts. (Korean J Anesthesiol 2010; 58: 290-295)

Key Words: Heart, Myocardial stunning, Postconditioning, Reperfusion injury.
Introduction

Because pretreatment with ischemic or pharmacological preconditioning is seldom possible in patients with ongoing acute myocardial infarction, strategies that directly target reperfusion could be more reliable. In this regard, ischemic postconditioning (I-Post) and pharmacological postconditioning (P-Post) have generated considerable interest recently. I-Post, which entails brief repetitive mechanical interruptions during early reperfusion, has reduced myocardial infarction in dogs [1], rodents [2], and even humans [3]. The infarct limitation effect by I-Post is as effective as that of ischemic preconditioning (I-Pre) [1]. In addition, P-Post with various adjuvants, such as opioid, bradykinin, insulin, and urocontin, has also been shown to provide cardioprotection [4-7].

N,N,N’N’-Tetrakis-[2-pyridylmethyl]-ethylenediamine (TPEN) is a high-affinity chelator of transition metals, such as Zn$^{2+}$. TPEN also binds Ca$^{2+}$ with a low affinity, and its fast diffusion across membranes renders it an intracellular Ca$^{2+}$ buffer [8]. It has been proposed that ischemic pretreatment with TPEN confers cardioprotection in rat cardiomyocytes [9] and hearts [10], and TPEN treatment before and during hypoxia induces activation of a sarcolemmal Na$^{+}$/Ca$^{2+}$ exchanger and increases Ca$^{2+}$ extrusion from the cytoplasm of cardiomyocytes, preventing cytosolic Ca$^{2+}$ overload in cultured cardiomyocytes [9]. Furthermore, TPEN administered prior to ischemia has exerted beneficial effects on post-ischemic cardiac function; it has also reduced ventricular fibrillation (VF) incidence as well as the incidence and duration of ventricular tachycardia in in vivo rat hearts [10]. However, the TPEN induced myocardial infarct limitation effect, which is considered a more reliable endpoint than functional recovery [11], has not been characterized.

Interestingly, some drugs protect the myocardium against ischemic injury but not against reperfusion injury and vice versa [12-14]. In this regard, it should be determined whether TPEN also provides cardioprotection when administered during the reperfusion period, which is a more suitable management time in clinical settings. Thus far, however, there is scant information about targeting TPEN during the reperfusion phase and the subsequent effects it would have on infarct limitation and cardiac function recovery.

Therefore, in this study, we examined whether P-Post with TPEN at the concentrations that are cardioprotective against ischemia could reduce myocardial infarct size and induce cardiodynamic functional recovery in an isolated rat heart model.

Materials and Methods

Langendorff isolated heart perfusion preparation

Male Sprague-Dawley rats (280−330 gm) were obtained from Korea Taconic Company. Rats were anesthetized with 100 mg/kg of pentobarbital sodium (Entobar®, Hanlim Pharmacy, Korea), and 300 IU of heparin was administered intraperitoneally. Coronary perfusion by the Langendorff system with modified Krebs-Henseleit (KH) solution, containing 118.5 NaCl, 4.7 KCl, 1.2 MgSO$_4$, 1.8 CaCl$_2$, 24.8 NaHCO$_3$, 1.2 KH$_2$PO$_4$, and 10 glucose (in mM), was performed as previously described in detail in our previous reports [15,16].

Making of ischemia and reperfusion

All hearts were allowed to stabilize for at least 20 min before ischemia induction. Hearts were subjected to 30 min of regional ischemia and 120 min of reperfusion. To induce regional ischemia, a snare was made at the level of the proximal length of the left coronary artery (LCA). Regional ischemia was induced by pulling the snare and confirmed by regional cyanosis and a substantial decrease in left ventricular developed pressure (LVDP). Reperfusion was started by releasing the snare. Hearts experiencing VF after reperfusion usually revert spontaneously to sinus rhythm. VF lasting more than 30 s was treated with finger flick cardioversion until a perfusing rhythm was obtained. No pharmacological agents were used for defibrillation.

Assessment of cardiac function

In isolated hearts, a KH buffer-filled latex balloon was inserted into the left ventricle (LV) and was adjusted to 5−10 mmHg of the left ventricular end-diastolic pressure (LVEDP) at the beginning of the experiment. Cardiodynamic variables, including heart rate (HR), left ventricular systolic pressure (LVSP), and LVEDP, were recorded with the MP150 system (BIOPAC Systems Inc., USA). LVDP and rate-pressure product (RPP) were calculated as follows: LVDP = LVSP − LVEDP and RPP = LVDP × HR. Maximum (+dP/dt$_{max}$) and minimum (−dP/dt$_{min}$) of the first derivative of LV pressure were analyzed using the Acqknowledge software (version 3.9.0.). Coronary flow (CF) was measured by perfusate dripping from the right heart into a graduated cylinder.

Experimental protocol

Isolated rat hearts were assigned randomly to one of the following two groups: 1) Control; no other intervention either before or after LCA occlusion (n = 9), and 2) TPEN; 10 μM
of TPEN (n = 8). TPEN (Sigma-Aldrich Chemical, USA) was infused for a period of 5 min before and 30 min after reperfusion (Fig. 1). TPEN was dissolved with dimethyl sulfoxide and stored at -20°C. TPEN was diluted with KH solution to the required final concentrations, as described above, on the day of each experiment. The concentration of TPEN used in this study was based on a previous study for isolated working rat hearts [10].

Exclusion criteria

We decided prospectively that any hearts with a HR < 250 beats/min, those failing to develop LVSP > 80 mmHg when the LVEDP was kept at 5–10 mmHg, or CF > 18 ml/min or < 8 ml/min at the end of stabilization would be excluded from the study.

Determination of ischemic and infarct zone

At the end of each experiment (2 h reperfusion), ischemic (area at risk, AR) and infarcted (area of necrosis, AN) regions were measured with fluorescent polymer microspheres (Duke Scientific Corp., USA) and 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich Chemical, USA) staining as described previously [15]. The AR and AN regions were quantified with the ImageTool program (UTHSCSA Image Tool, version 3.0). Infarct size was expressed as a percentage of the risk zone (AN/AR). All measurements were performed in a blinded fashion. Body weight (mean 302.2 ± 4.4 gm) and heart weight (mean 1.54 ± 0.04 gm) were equivalent between the two groups.

Statistical analysis

Data are expressed as means ± SEM. Statistical significance was determined using a t-test (SPSS for Windows, version 12.0). A P value less than 0.05 was considered to be statistically significant.

Results

All hearts for this experiment were perfused within 30 s after excision. A total of 19 rat hearts were used for the infarct size measurement study. Two hearts were excluded for the following reasons: HR < 250 beats/min (1) and CF > 18 ml/min (1) after the stabilization period. Therefore, we report the data for 17 hearts that successfully completed the infarct experiment study. The incidence of VF during the first 30 min after reperfusion was 67% (6/9) in the control group and 62% (5/8) in the TPEN group, respectively. Statistical analysis was not performed for the occurrence of VF, because of the small sample size. Hearts experiencing VF after reperfusion usually reverted to sinus rhythm spontaneously or by finger flick cardioversion.

Infarct size

Fig. 2 represents the AN/AR ratio after 2 h of reperfusion by TTC stain. AN in control hearts was 29.5 ± 3.2% of the AR, which is in agreement with our recently reported infarct measurement study [15,16]. AN/AR of the TPEN group was significantly reduced (6.9 ± 1.7%) compared to control hearts (P < 0.001).

Functional recovery

Baseline CF and HR after stabilization are shown in Table 1 and were comparable between the groups, averaging 11.8 ± 0.5 ml/min and 273.6 ± 3.1 beats/min, respectively. CF abruptly decreased after ischemia and diminished continuously during reperfusion without achieving statistically significant differences between
Kim, et al.

There was no statistically significant difference in HR throughout the experiment between the groups (data not shown).

Baseline values of cardiodynamic parameters after stabilization are also shown in Table 1. There was no significant difference in baseline cardiodynamic parameters between the two groups (P > 0.05). Fig. 3 shows recovery of LVDP, RPP, +dP/dt\textsubscript{max} and −dP/dt\textsubscript{min} after 2 h of reperfusion compared to baseline levels. There were no significant differences in cardiodynamic variables between the two groups (P > 0.05).

**Table 1. Baseline Coronary Flow and Cardiodynamic Data after Stabilization**

| Group   | Coronary flow (ml/min) | Heart rate (beats/min) | LVDP (mmHg) | RPP (mmHg\cdot beats/min\cdot 10\textsuperscript{-3}) | +dP/dt\textsubscript{max} (mmHg/s/10\textsuperscript{-3}) | −dP/dt\textsubscript{min} (mmHg/s/10\textsuperscript{-3}) |
|---------|------------------------|------------------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Control | 12.6 ± 0.6             | 270.9 ± 5.0            | 130.3 ± 4.3 | 35.3 ± 1.4                                    | 3.0 ± 0.3                                      | −2.7 ± 0.2                                    |
| TPEN    | 11.0 ± 0.5             | 276.8 ± 3.4            | 139.9 ± 6.9 | 38.7 ± 2.0                                    | 2.8 ± 0.2                                      | −2.7 ± 0.2                                    |

Values are means ± SEM. TPEN: N,N,N’,N’-tetrakis-[2-pyridylmethyl]-ethylenediamine, LVDP: left ventricular developed pressure, RPP: rate-pressure product, +dP/dt\textsubscript{max}: velocity of contraction, −dP/dt\textsubscript{min}: velocity of relaxation. There are no significant differences between groups (t-test).

The two groups. There was no statistically significant difference in HR throughout the experiment between the groups (data not shown).

Baseline values of cardiodynamic parameters after stabilization are also shown in Table 1. There was no significant difference in baseline cardiodynamic parameters between the two groups (P > 0.05). Fig. 3 shows recovery of LVDP, RPP, +dP/dt\textsubscript{max} and −dP/dt\textsubscript{min} after 2 h of reperfusion compared to baseline levels. There were no significant differences in cardiodynamic variables between the two groups (P > 0.05).

**Discussion**

TPEN is a drug that was proposed to protective against myocardial ischemic injury and reduce post-ischemic cardiac damage [17]. Until now, most of the studies on TPEN’s cardioprotective effect were performed on ischemic pretreatment, and the effect of P-Post with TPEN remained. The present study has shown for the first time that targeting the use of TPEN, a metal chelator, during the reperfusion phase limits myocardial infarction. In addition, the study showed that there were no differences in cardiodynamic parameters, such as LVDP, RPP, +dP/dt\textsubscript{max} and −dP/dt\textsubscript{min} between TPEN-treated and non-treated hearts. Our data showed that P-Post with TPEN reduces myocardial infarct size but does not improve the functional recovery after reperfusion in isolated rat hearts.

Although tissue salvage by an anti-infarct intervention leads to improvement of cardiac function, infarct size limitation does not always produce mechanical functional recovery of hearts after myocardial ischemic/reperfusion (I/R) injury. For example, a potent opioid such as fentanyl, or angiotensin II reduces infarct size but does not protect against myocardial dysfunction in isolated rat hearts [18,19]. In addition, there are also several lines of evidence that I-Pre and I-Post also limit infarct size but do not reduce myocardial dysfunction [20,21]. The adenosine receptor agonist AMP579 or nitric oxide donors, on the other hand, alleviate both myocardial infarct size and dysfunction [22,23]. The discrepancy between infarct limitation and cardiac function recovery may be explained by continued stunning, or the possibility that the salvaged tissue is not yet normal [11]. Myocardial stunning is prolonged myocardial dysfunction with the histological absence of necrosis after I/R injury. It is proposed that stunning occurs in reversibly injured cells or via nonlethal injury to the epicardial border zones surrounding infarcted myocardium [24]. Although cellular ATP levels or free radicals have been proposed to be important mediators for stunning [25], the exact mechanism responsible for stunning remains unclear. Another possible mechanism for myocardial stunning is an increase in the concentration of intracellular Ca\textsuperscript{2+}. The increase in the Ca\textsuperscript{2+} concentrations in myocardial cells is likely explains the depressed ability of I/R hearts to generate contractile force [26]. In our present study, targeting TPEN during the reperfusion period reduced myocardial infarction but did not attenuate post-ischemic systolic dysfunction, even though TPEN has a Ca\textsuperscript{2+} buffer action. We do not know the exact reason for this, but the Ca\textsuperscript{2+} buffer action of the TPEN concentration (10 μM) used during reperfusion might not be enough to attenuate myocardial systolic dysfunction.

It has been previously demonstrated that TPEN reduces basal cardiac nitric oxide (NO) content and prevents the
accumulation of NO during myocardial I/R [9]. In addition it has been proposed that lowering sarcolemmal Ca\(^{2+}\) content may be a mechanism underlying the recently reported cardioprotective and anti-arrhythmic features of TPEN [9,10]. A chelator is a substance consisting of molecules that bind tightly to metal atoms, thus forcing the metal atoms to go wherever the chelator goes. Though TPEN has been used mainly as a heavy metal (e.g. Zn\(^{2+}\)) chelator, it has a low affinity for Ca\(^{2+}\) as well and its fast diffusion across membranes make TPEN a membrane permeable buffer for Ca\(^{2+}\) within intracellular stores [8]. Recently, Shmist et al. [9] demonstrated that TPEN improves myocardial protection against ischemia by modulation of intracellular Ca\(^{2+}\) homeostasis. Jung et al. [27] also demonstrated that myocardial protection by TPEN has been related to its modulation of Ca\(^{2+}\) homeostasis through the activation of the Na\(^+\)/Ca\(^{2+}\) exchanger leading to increased extrusion of Ca\(^{2+}\) from the cytoplasm in ventricular myocytes. However, the exact mechanism of the cardioprotective effect achieved by targeting the administration of TPEN during the reperfusion period has not yet been well established and should be determined in the future.

Interestingly, some drugs protect the myocardium when used during the ischemic phase but not in the reperfusion phase and vice versa [12-14]. In this study, administrating TPEN during the reperfusion phase effectively reduced myocardial infarction. Taken together with other previous reports on the effect of PEN treatments targeting ischemia [8,9], one can propose that TPEN has anti-ischemic and reperfusion injury protective effects.

It is also interesting that TPEN acts as a membrane permeable Zn\(^{2+}\) chelator, i.e., TPEN reduces intracellular Zn\(^{2+}\) concentrations. Zn\(^{2+}\) is essential in maintaining the structure and function of cell membranes, and it plays an important role in the maintenance of the activity of various enzymes [28]. Recently, several lines of evidence documented that exogenous Zn\(^{2+}\) may lead to cardioprotection against reperfusion injury [29,30]. In our study, TPEN administration during the reperfusion phase significantly reduced myocardial infarction, even though TPEN reduces intracellular Zn\(^{2+}\) concentrations. The reason for this is unclear, but we can propose that the Ca\(^{2+}\) buffering effect of TPEN may be a more important mechanism for the limitation of infarction than the ability to lower the Zn\(^{2+}\) concentration.

We conclude that P-Post with a 10 μM concentration of TPEN, which is proposed to have a cardioprotective effect during ischemia, limits myocardial infarction but does not attenuate myocardial dysfunction in isolated rat hearts. Further studies are needed to determine the exact mechanism for this discrepancy.

References

1. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-88.

2. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004; 62: 74-85.

3. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007; 19: 424–30.

4. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-6.

5. Park SS, Zhao H, Mueller RA, Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3-beta. J Mol Cell Cardiol 2006; 40: 708-16.

6. Baines CP, Wang L, Cohen MV, Downey JM. Myocardial protection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 1999; 94: 188-98.

7. Gordon JM, Dusting GJ, Woodman OL, Ritchie RH. Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2003; 284: H330-6.

8. Shumaker DK, Vann LR, Goldberg MW, Allen TD, Wilson KL. TPEN, a Zn\(^{2+}\)/Fe\(^{3+}\) chelator with low affinity for Ca\(^{2+}\), inhibits lamin assembly, destabilizes nuclear architecture and may independently protect nuclei from apoptosis in vitro. Cell Calcium 1998; 23: 151-64.

9. Shmist YA, Kamburg R, Ophir G, Kozak A, Shneyvays V, Appelbaum YJ, et al. N,N,N’,N’-tetrakis(2-pyridylmethyl)-ethylenediamine improves myocardial protection against ischemia by modulation of intracellular Ca\(^{2+}\) homeostasis. J Pharmacol Exp Ther 2005; 313: 1046-57.

10. Ferdinandy P, Appelbaum Y, Csonka C, Blasig IE, Tosaki A. Role of nitric oxide and TPEN, a potent metal chelator in ischemic and reperfused rat isolated hearts. Clin Exp Pharmacol Physiol 1998; 25: 496-502.

11. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Basic Res Cardiol 2003; 98: 337-46.

12. Ebel D, Lipfert P, Frässdorf J, Preckel B, Müllenhain J, Thämer V, et al. Lidocaine reduces ischaemic but not reperfusion injury in isolated rat hearts. Br J Anaesth 2001; 86: 846-52.

13. Goto M, Miura T, Ilidioromitis EK, O’Leary EL, Ishimoto R, Yellon DM, et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 1991; 25: 943-9.

14. Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996; 31: 711-8.
15. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z, et al. Post-conditioning prevents reperfusion injury by activating \( \delta \)-opioid receptors. Anesthesiology 2008; 108: 243-50.

16. Song DK, Jang YH, Lee DH, Kim JH, Chun KJ, Xu Z, et al. Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K\(_{\text{ATP}}\) channel activation in isolated rat hearts. J Korean Med Sci 2010; 25: 380-6.

17. Appelbaum YJ, Kuvin J, Borman JB, Uretzky G, Chevion M. The protective role of neocuproine against cardiac damage in isolated perfused rat hearts. Free Radic Biol Med 1990; 8: 133-43.

18. Kato R, Foex P. Fentanyl reduces infarction but not stunning via delta opioid receptors and protein kinase C in rats. Br J Anaesth 2000; 84: 608-14.

19. Ford WR, Clanachan AS. Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts. Br J Pharmacol 2001; 134: 38-45.

20. Jenkins DP, Pugsley WB, Yellon DM. Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning. J Mol Cell Cardiol 1995; 27: 1623-32.

21. Couvreur N, Lucats L, Tissier R, Bize A, Berdeaux A, Ghaleh B. Differential effects of postconditioning on myocardial stunning and infarction: a study in conscious dogs and anesthetized rabbits. Am J Physiol Heart Circ Physiol 2006; 291: H1345-50.

22. Shimamura K, Tang XL, Takano H, Hill M, Bolli R. Nitric oxide donors attenuate myocardial stunning in conscious rabbits. Am J Physiol 1999; 277: H2495-503.

23. Yoshimura Y, Kristo G, Keith BJ, Jahania SA, Mentzer RM Jr, Lasley RD. The p38 MAPK inhibitor SB203580 blocks adenosine A(1) receptor-induced attenuation of in vivo myocardial stunning. Cardiovasc Drugs Ther 2004; 18: 433-40.

24. Bush LR, Buja LM, Samowitz W, Rude RE, Wathen M, Tilton GD, et al. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Comparison of 2- and 4-hours occlusions. Circ Res 1983; 53: 248-63.

25. Kloner RA, DeBoer LW, Darsee JR, Ingwall JS, Hale S, Tumas J, et al. Prolonged abnormalities of myocardium salvaged by reperfusion. Am J Physiol 1981; 241: H591-9.

26. Meissner A, Morgan JP. Contractile dysfunction and abnormal Ca\(^{2+}\) modulation during postischemic reperfusion in rat heart. Am J Physiol 1995; 268: H100-11.

27. Jung C, Zima AV, Szentesi P, Jona I, Blatter LA, Niggle E, et al. Ca\(^{2+}\) release from the sarcoplasmic reticulum activated by the low affinity Ca\(^{2+}\) chelator TPEN in ventricular myocytes. Cell Calcium 2007; 41: 187-94.

28. O’Dell BL. Zinc plays both structural and catalytic roles in metalloproteins. Nutr Rev 1992; 50: 48-50.

29. Chanoit G, Lee S, Xi J, Zhu M, McIntosh RA, Mueller RA, et al. Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta. Am J Physiol Heart Circ Physiol 2008; 295: H1227-33.

30. Lee S, Chanoit G, McIntosh R, Zvara DA, Xu Z. Molecular mechanism underlying Akt activation in zinc-induced cardioprotection. Am J Physiol Heart Circ Physiol 2009; 297: H569-75.